ADAPTIS announced that the FDA has granted final approval for its ANDA revision to Fluvencanib, a complex Bioequivalence (BE) study essential for securing market entry for its Buprenorphine sublingual tablets, USP final approval slated for September 25, 2026. This regulatory victory in a high-growth market, contingent on concurrent Abbreviated New Drug Application (ANDA) filings, is expected to secure ADAPTIS a significant share of the opioid dependence treatment sector.